Emerging Technological Landscapes in Biomanufacturing and Monoclonal Antibody Screening

Emerging technologies are transforming biomanufacturing and monoclonal antibody (mAb) screening by enabling greater process control, automation, and real-time analytics. Process Analytical Technology (PAT) and Multi-Attribute Methods (MAM) are advancing from offline assays to integrated, near-real-time systems that monitor critical quality attributes like glycosylation and host cell protein levels. These innovations improve product consistency, accelerate decision-making, and reduce manufacturing risk. As the industry moves toward continuous and automated production, such tools are vital for achieving regulatory alignment, ensuring product quality, and enhancing patient outcomes across the rapidly growing biologics landscape.